PMID- 21860342
OWN - NLM
STAT- MEDLINE
DCOM- 20120126
LR  - 20211020
IS  - 1536-3694 (Electronic)
IS  - 0163-4356 (Print)
IS  - 0163-4356 (Linking)
VI  - 33
IP  - 5
DP  - 2011 Oct
TI  - MDMA and metabolite disposition in expectorated oral fluid after controlled oral 
      MDMA administration.
PG  - 602-8
LID - 10.1097/FTD.0b013e3182281975 [doi]
AB  - INTRODUCTION: The use of 3,4-methylenedioxymethamphetamine (MDMA) is increasing, 
      enhancing the need for its detection in clinical, workplace, pain management, and 
      driving under the influence of drugs testing programs. Oral fluid is an important 
      alternative matrix for drug testing, but little is known about MDMA detection 
      windows in oral fluid. AIMS: The aim was to characterize MDMA and metabolite 
      disposition in expectorated oral fluid after controlled MDMA administration. 
      METHODS: Placebo, low (1.0 mg/kg), and high (1.6 mg/kg) oral MDMA doses were 
      given double-blind in random order in separate sessions to 29 healthy adults with 
      histories of MDMA use. One thousand two hundred eighty-six expectorated oral 
      fluid specimens collected up to 7 days after dosing were analyzed for MDMA, 
      3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxymethamphetamine (HMMA), 
      and 4-hydroxy-3-methoxyamphetamine (HMA) by gas chromatography mass spectrometry. 
      The limits of quantification were 5 ng/mL for MDMA and MDA and 10 ng/mL for HMA 
      and HMMA. RESULTS: MDMA was the primary analyte detected, with concentrations up 
      to 12,000 ng/mL in 872 specimens (67.8%). MDA was quantified in 656 specimens 
      (51.0%) at concentrations <403 ng/mL and was never present without concurrent 
      MDMA. HMA and HMMA were not detected. Of the specimens, 59.8%, 58.6%, and 54.9% 
      were found to be MDMA positive at the Talloires (20 ng/mL), Driving under the 
      Influence of Drugs, Alcohol, and Medicines (25 ng/mL) and proposed US Substance 
      Abuse and Mental Health Services Administration (50 ng/mL) confirmation cutoffs, 
      respectively. MDMA was first observed in oral fluid 0.25-1.25 hours after dosing; 
      MDA was initially detected at 0.5-1.75 hours. In general, the windows of 
      detection for MDMA and MDA were 47 and 29 hours, respectively, although a few 
      specimens were positive up to 71 and 47 hours. CONCLUSIONS: Oral fluid monitoring 
      efficiently detects single, recreational 70-150 mg of MDMA use for 1-2 days. 
      These controlled administration data provide a scientific basis for interpreting 
      MDMA oral fluid test results.
FAU - Barnes, Allan J
AU  - Barnes AJ
AD  - Chemistry and Drug Metabolism, National Institute on Drug Abuse, National 
      Institutes of Health, Baltimore, Maryland, USA.
FAU - Scheidweiler, Karl B
AU  - Scheidweiler KB
FAU - Kolbrich-Spargo, Erin A
AU  - Kolbrich-Spargo EA
FAU - Gorelick, David A
AU  - Gorelick DA
FAU - Goodwin, Robert S
AU  - Goodwin RS
FAU - Huestis, Marilyn A
AU  - Huestis MA
LA  - eng
GR  - Z01 DA000468-04/Intramural NIH HHS/United States
GR  - Z01 DA000468-05/Intramural NIH HHS/United States
GR  - ZIA DA000468-06/Intramural NIH HHS/United States
GR  - ZIA DA000468-07/Intramural NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Ther Drug Monit
JT  - Therapeutic drug monitoring
JID - 7909660
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Cross-Over Studies
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & 
      dosage/*analysis/*metabolism/pharmacokinetics
MH  - Saliva/*chemistry
MH  - Young Adult
PMC - PMC3178664
MID - NIHMS310508
EDAT- 2011/08/24 06:00
MHDA- 2012/01/27 06:00
PMCR- 2012/10/01
CRDT- 2011/08/24 06:00
PHST- 2011/08/24 06:00 [entrez]
PHST- 2011/08/24 06:00 [pubmed]
PHST- 2012/01/27 06:00 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
AID - 10.1097/FTD.0b013e3182281975 [doi]
PST - ppublish
SO  - Ther Drug Monit. 2011 Oct;33(5):602-8. doi: 10.1097/FTD.0b013e3182281975.